EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients

Takeshi Okamoto iD, Tsuyoshi Takeda iD, Takashi Sasaki iD, Tsuyoshi Hamada iD, Takafumi Mie iD, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Tatsuki Hirai, Takaaki Furukawa, Akiyoshi Kasuga iD, Masato Ozaka und 1 weitere

Current Oncology · 2023

DOI: 10.3390/curroncol30080524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Takeshi Okamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo…. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Carcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The safety and effectiveness of chemotherapy in elderly patients with biliary tract cancer (BTC) remain unclear. Therefore, we retrospectively reviewed patients who underwent chemotherapy for locally advanced, metastatic, or recurrent BTC at our institution from January 2016 to December 2021. Of the 283 included patients, 91 (32.5%) were aged 75 years or older when initiating chemotherapy. Elderly patients were more likely than non-elderly patients to receive monotherapy with gemcitabine or S-1 (58.7% vs. 9.4%, p < 0.001) and were less likely to experience grade 3–4 toxicities (55.4% vs. 70.2%, p = 0.015). The rates of termination due to intolerance (6.5% vs. 5.8%, p = 0.800) and transition to second-line chemotherapy (39.1% vs. 40.3%, p = 0.849) were similar between groups. In the overall cohort, age was not an independent predictor of overall survival (OS). Within the elderly cohort, there were no differences in severe adverse events between patients receiving monotherapy and combination therapy (50.0% vs. 63.2%, p = 0.211). Median OS was longer in the combination therapy group (10.4 vs. 14.1 months; p = 0.010); however, choice of monotherapy was not an independent predictor of overall survival. Monotherapy appears to be a viable alternative in selected elderly BTC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsCarcinomaHumansMiddle AgedRetrospective StudiesCombined Modality TherapyGemcitabine

Stichwörter der Autor:innen

S-1agecholangiocarcinomacisplatincombination chemotherapygemcitabinemonotherapytolerability

Substanzen

Gemcitabine

Autor:innen und Institutionen

  • Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
  • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan.

ORCID-Profile: Takeshi Okamoto, Tsuyoshi Takeda, Takashi Sasaki, Tsuyoshi Hamada, Takafumi Mie, Akiyoshi Kasuga, Naoki Sasahira

Zitieren

APA

Okamoto, T., Takeda, T., Sasaki, T., Hamada, T., Mie, T., Ishitsuka, T., Yamada, M., Nakagawa, H., Hirai, T., Furukawa, T., Kasuga, A., Ozaka, M., & Sasahira, N. (2023). Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients. Current Oncology. https://doi.org/10.3390/curroncol30080524

Vancouver

Okamoto T, Takeda T, Sasaki T, Hamada T, Mie T, Ishitsuka T, et al. Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients. Current Oncology. 2023. doi:10.3390/curroncol30080524

BibTeX
@article{Okamoto2023,
  author = {Okamoto, Takeshi and Takeda, Tsuyoshi and Sasaki, Takashi and Hamada, Tsuyoshi and Mie, Takafumi and Ishitsuka, Takahiro and Yamada, Manabu and Nakagawa, Hiroki and Hirai, Tatsuki and Furukawa, Takaaki and Kasuga, Akiyoshi and Ozaka, Masato and Sasahira, Naoki},
  title = {Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30080524}
}
Kostenlos starten →